Abs 0412 by @Spondy_MD et al at #ACR22: BKZ tx showed meaningful improvements in physical function and HRQoL in nr-axSpA and AS pts with consistent responses. @RheumNow https://t.co/diGqpQKfpS https://t.co/1pdGi47IJM

• Bimekizumab Improves Physical Function and Health-Related Quality of Life in Pa…

Another study showing treatment withdrawal does not work. Golimumab withdrawal in nr-axSpA is inferior to continued treatment or tapered treatment, leading to more disease flares. Abs#0545 @RheumNow #ACR22 https://t.co/CBRnVdxXVo

2022 ASAS-EULAR recommendation lit review in Abs 0413 at #ACR22 shows new evidence on education & exercise and confirms efficacy in axSpA. Tofa, UPA, FIL have shown efficacy in r-axSpA. @RheumNow https://t.co/8E9RZQ8Gz4 https://t.co/5QPO5eddFH

• Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A System…

Interesting findings from Abs 0417 - when early axSpA is defined by duration of symptoms, only nr-axSpA tx w/ bDMARDs may lead to better outcomes vs early or established axSpA. #ACR22 @RheumNow https://t.co/8aGdyJRvv1 https://t.co/chAEGPicPd

• Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Lit…

NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy. *Numerical reduction in syndesmophytes 11% vs. 25% Abs#0546 @RheumNow #ACR22 #ACRBest https://t.co/pG5F3xdsh9

Abs 0419 SELECT-AXIS 2, UPA improved outcomes vs PBO in nr-axSpA pts across all BL inflammation subgroups; greatest benefit obs in pts with both elevated CRP and inflammation on baseline MRI. #ACR22 @RheumNow https://t.co/opaFwXgcvU https://t.co/o27ULcL8Ip

• Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthri…

#Abstr 0545 GO-BACK Trial Continue vs Withdrawal of GOL in nr-axSpA with inactive disease - Full tx withdrawal associated w/ dx flare - Re-treatment -->rapid clinical response after flare - qMonthly tx --> higher rates of disease activity improvement @RheumNow #ACR22 https://t.co/Z3bhA9D4RQ

#ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after 1 yr were generally sustained over 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI numerically highest in MRI+/CRP+. @RheumNow https://t.co/cjpp2qCN4O https://t.co/G2YjF6ubUf

• Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Ac…

Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR (BASDAI/ASDAS). Post hoc analysis AxSpA on Certolizumab. Majority of patients >50% improved OIR, only minority improved CR. Rudwaleit etal https://t.co/WdkmkCWClO #ACR22 @RheumNow https://t.co/qlNUFhnuJQ

• An Exploratory Analysis of the Potential Disconnect Between Objective Inflammat…

2022 ASAS-EULAR Recommendations of AxSpA management 1) NSAIDs still first line 2) Analgesics/opioids contraindicated 3) TNFi, IL-17i first line bDMARDs, followed by JAKinibs 4) Tapering but not discontinuation of bDMARDs in sustained remission Abs#0542 @RheumNow #ACR22 https://t.co/ffaN2fMc3v